Allogeneic lymphocyte therapy (Fred Hutchinson Cancer Research Center/National Cancer Institute)

N/A

Report date: 2024/07/05 11:15:17

Base Information

Drug NameAllogeneic lymphocyte therapy (Fred Hutchinson Cancer Research Center/National Cancer Institute)
Drug Alias NameALLOLYMPHTherapeutic Allogeneic LymphocytesAllogeneic LymphocytesTumor-Derived LymphocyteTherapeutic allogeneic lymphocytes (Fred Hutchinson)
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Memory T cell therapy
Mechanisms of ActionLymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsPrimary MyelofibrosisMyelodysplastic SyndromesAnemia, Aplastic +[33] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesItalyGermany
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesFred Hutchinson Cancer Research CenterNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesSidney Kimmel Cancer Center At Thomas Jefferson University
Inactive CompaniesNational Cancer InstituteFred Hutchinson Cancer Research Center
Active IndicationsPrimary MyelofibrosisMyelodysplastic SyndromesAnemia, Aplastic +[13] 
Inactive IndicationsHeart ArrestRenal InsufficiencyWaldenstrom Macroglobulinemia +[20] 

Other Information

ATC CodeN/A
Related LinksN/A